Scholarlink

Background <p>Sulfotransferase family 1E member 1 (SULT1E1) is a key estrogen-metabolizing enzyme whose dysregulation has been implicated in several hormone-related malignancies. However, its expression pattern, biological function, and clinical significance in hepatocellular carcinoma (HCC) remain poorly understood.</p> Methods <p>SULT1E1 expression was analyzed in HCC tissues and cell lines using public datasets (TCGA and GEO) and a retrospective cohort of 85 HCC patients. Gain-of-function experiments were performed to evaluate the effects of SULT1E1 on HCC cell proliferation, migration, stem-like properties, and cell cycle progression in vitro. Transcriptomic profiling, pathway enrichment analyses, and pharmacological inhibition were used to explore underlying mechanisms. Subcutaneous and orthotopic xenograft mouse models were employed to assess the in vivo effects of SULT1E1.</p> Results <p>SULT1E1 expression was significantly downregulated in HCC tissues and cell lines and was associated with poor prognosis. Overexpression of SULT1E1 suppressed HCC cell proliferation, migration, colony formation, and tumorsphere formation, while inducing G1 phase cell cycle arrest. Transcriptomic and enrichment analyses indicated that SULT1E1 is involved in the regulation of cell cycle–related pathways and activation of the TGF-β/SMAD signaling pathway. Mechanistically, SULT1E1 overexpression increased SMAD2/3 phosphorylation, and pharmacological inhibition of TGF-β signaling partially reversed its tumor-suppressive effects. In vivo, SULT1E1 overexpression significantly inhibited tumor growth in HCC xenograft models.</p> Conclusions <p>SULT1E1 functions as a tumor suppressor in hepatocellular carcinoma by restraining cell proliferation, migration, and stem-like properties, at least in part through activation of the TGF-β/SMAD signaling pathway and induction of cell cycle arrest. These findings suggest that SULT1E1 may serve as a potential prognostic biomarker and therapeutic target in HCC.</p> Trial registration <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SULT1E1 suppresses hepatocellular carcinoma progression via activation of the TGF-β/SMAD signaling pathway and cell cycle arrest

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月11日

查看全文
  • Wenjun Zhang,
  • Junlu Peng,
  • Dafei Dai,
  • Chen Huang,
  • Fubao Liu,
  • Xiaopeng Chen

摘要

Background

Sulfotransferase family 1E member 1 (SULT1E1) is a key estrogen-metabolizing enzyme whose dysregulation has been implicated in several hormone-related malignancies. However, its expression pattern, biological function, and clinical significance in hepatocellular carcinoma (HCC) remain poorly understood.

Methods

SULT1E1 expression was analyzed in HCC tissues and cell lines using public datasets (TCGA and GEO) and a retrospective cohort of 85 HCC patients. Gain-of-function experiments were performed to evaluate the effects of SULT1E1 on HCC cell proliferation, migration, stem-like properties, and cell cycle progression in vitro. Transcriptomic profiling, pathway enrichment analyses, and pharmacological inhibition were used to explore underlying mechanisms. Subcutaneous and orthotopic xenograft mouse models were employed to assess the in vivo effects of SULT1E1.

Results

SULT1E1 expression was significantly downregulated in HCC tissues and cell lines and was associated with poor prognosis. Overexpression of SULT1E1 suppressed HCC cell proliferation, migration, colony formation, and tumorsphere formation, while inducing G1 phase cell cycle arrest. Transcriptomic and enrichment analyses indicated that SULT1E1 is involved in the regulation of cell cycle–related pathways and activation of the TGF-β/SMAD signaling pathway. Mechanistically, SULT1E1 overexpression increased SMAD2/3 phosphorylation, and pharmacological inhibition of TGF-β signaling partially reversed its tumor-suppressive effects. In vivo, SULT1E1 overexpression significantly inhibited tumor growth in HCC xenograft models.

Conclusions

SULT1E1 functions as a tumor suppressor in hepatocellular carcinoma by restraining cell proliferation, migration, and stem-like properties, at least in part through activation of the TGF-β/SMAD signaling pathway and induction of cell cycle arrest. These findings suggest that SULT1E1 may serve as a potential prognostic biomarker and therapeutic target in HCC.

Trial registration

Not applicable.